Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or academic setting, having a team that you can communicate with is critical.
We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
UPPSALA, SE / ACCESS Newswire / March 18, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based biomarkers for cancer treatment monitoring, today ...
A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Andreas Lundqvist's group will use Pixelgen's Proximity Network Assay to explore spatial distribution and abundance of single cell surface proteins in non-small cell lung cancer STOCKHOLM, March 17, ...
The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...
Net Loss: Net loss attributable to Cullinan was $50.7 million for the fourth quarter of 2025, compared to $47.6 million for the same period in 2024, and $219.9 million for the full year 2025, compared ...
CLEVELAND, March 10, 2026 /PRNewswire/ -- Oncologists currently have limited tools to predict which lung cancer patients will benefit from immunotherapy. The publication of a multi-institutional study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results